To determine the optimal surveillance approach in the setting of locally-advanced nonesmall-cell lung cancer (NSCLC) treated with definitive radiation, we compared 2 commonly used strategies, positron emission tomography (PET)/computed tomography (CT)-based and CT-based. There were no differences in baseline clinical or treatment characteristics or any of the survival outcomes examined between the 2 groups. These results suggest that routine PET/CT imaging after definitive radiation treatment for locally-advanced NSCLC confers no benefit in early detection of recurrence.
Introduction
Lung cancer remains the leading cause of cancer mortality in the United States and has a 5-year survival rate of 17%. 1 This is due to the aggressive nature of the disease and its proclivity to recur after definitive treatment with surgery or radiation. Consequently, intensive surveillance might be necessary to detect recurrence. 2 Despite this, there is no consensus recommendation regarding the optimal post-treatment surveillance imaging modality or sequencing. Current National Comprehensive Cancer Network (NCCN) guidelines for nonesmall-cell lung cancer (NSCLC) recommend a chest computed tomography (CT) scan every 6 to 12 months after completion of treatment for 2 years followed by annual low-dose chest CT surveillance. 3 Furthermore, routine surveillance positron emission tomography (PET)/CT imaging is not recommended, predominantly because of the lack of data showing benefit. 4 However, PET/CT has quickly received widespread adoption during the initial staging evaluation and has become commonly used in the post-treatment surveillance window to assess for disease recurrence locally and distantly because of reported improvements in sensitivity and specificity in disease recurrence detection. 5, 6 Unfortunately, PET/CT imaging is costly and, thus, its potential overuse is subject to increasing scrutiny because of the national trend in improving oncologic care efficiency and cost effectiveness. Consequently, studies that inform when PET/CT should be used in post-treatment surveillance are needed. The limited analyses currently available have included small patient numbers and suboptimal comparison groups. [7] [8] [9] [10] Therefore, further analysis is needed to determine the role of PET/CT scan in surveillance for locally advanced NSCLC compared with CT scan with contrast, as recommended in national guidelines. 3 The aims of the current study were as follows: (1) determine if there are systematic differences between patients who undergo CT versus PET/CT surveillance after definitive radiation therapy (RT) for locally advanced NSCLC; (2) compare patterns of failure in patients who underwent each of these surveillance regimens; and (3) assess survival on the basis of the surveillance approach. We hypothesized that PET/CT surveillance would detect disease earlier, because of the increased sensitivity of this imaging modality and more comprehensive nature of full-body scanning, and that this earlier detection would lead to increased survival outcomes because of initiation of salvage therapy in the context of smaller-volume disease.
Materials and Methods

Patients and Imaging Data
After institutional review board approval, patients were selected from a clinical database of patients with pathologically confirmed NSCLC treated with definitive RT to a dose of 60 Gy at a single tertiary cancer center. Radiation treatment was begun from January 2000 to January 2011. Patient confidentiality was maintained in accordance with the Health Insurance Portability and Accountability Act. Four hundred ninety-four consecutively treated patients met the aforementioned criteria ( Figure 1A ). For the final cohort we used the following inclusion criteria: (1) stage III disease; (2) no events or deaths < 6 months after treatment; and (3) at least 2 surveillance scans must have been acquired. The first criteria was used to generate a population that was treated in a uniform fashion. The latter 2 criteria were adopted to ensure sufficient follow-up time and surveillance imaging to identify trends in a population of patients with a potentially long disease-free interval. For example, some patients who relapsed or died within the first 6 months after definitive radiation treatment either had none or only 1 surveillance scan. Many patients did not accumulate multiple post-treatment scans and, as a result, did not develop a pattern of surveillance imaging. Consequently, the imaging patterns in this group are highly heterogeneous and challenging to interpret. After applying the inclusion criteria, 200 patients were subsequently found to be eligible for analysis. PET/CT Versus CT Surveillance in Stage III NSCLC Imaging and relapse data were retrospectively collected from electronic medical records for patients who met the aforementioned criteria. All CT and PET/CT scans obtained after the completion of definitive RT were recorded. Of note, routine chest CT imaging for lung cancer patients at our institution extends to the level of the adrenal glands, which detects extrathoracic metastatic lesions in the upper abdomen.
Assessing Surveillance Methods
Over the past 10 years, there has been heterogeneity among the multiple treating physicians at our institution with regard to the choice of post-RT imaging. Two primary surveillance strategies are used. The first approach is CT scan at every surveillance visit, every 3 to 6 months for the first 5 years, and annually thereafter. The second approach is alternating PET/CT and CT scans for 1 to 2 years (because it is the biggest risk period), reserving PET/CT for abnormal findings on CT scan. Our objectives were first to compare patient, disease, and treatment characteristics between the 2 groups, and then to examine the treatment strategies according to the detection of recurrence and overall survival (OS).
As an initial step, scans taken before 1 month after treatment and those taken after disease relapse were excluded because these are not relevant to surveillance imaging. We then examined the distribution of post-RT images over time, to determine if there was a consistent pattern over an extended period that could be adequately evaluated ( Figure 1B ). This analysis revealed that the ratio of CT to PET/CT dramatically increases over time reflecting the practice of omitting routine PET/CT in patients who do not have local or distant failure in the initial 2 years after definitive radiation. Consequently, to compare a predominantly CT-based surveillance strategy with a PET/CT-based one, we elected to categorize patients into 2 distinct groups by focusing on surveillance imaging patterns immediately after definitive treatment. To categorize patients into these groups, the first 2 scans performed after radiation treatment were examined. If a PET/CT was performed during 1 of the initial 2 scans, the patient was categorized into the PET/CT group, whereas patients who only received CT scans as their initial 2 scans were categorized into the CT group. Critical to the current analysis was the absence of a systematic difference between patients who received PET/CT and CT scan. To show that there was not a systematic difference between patients who received PET/CT versus CT, we compared multiple characteristics between groups.
Statistical Methods
Survival curves were calculated using the KaplaneMeier method. Univariate and multivariate odds ratios associating relevant clinical variables were calculated via logistic regression. Variables analyzed included demographic data, stage (IIIA vs. IIIB), performance status, and chemotherapy. All tests were considered significant at P < .05. Analyses were performed using either SAS version 9.3 or JMP version 12 (SAS Institute Inc, Cary, NC).
Results
Patient Characteristics and Comparison Between PET/CT and CT Groups
A total of 200 patients with stage III NSCLC who were treated with definitive radiation met our study inclusion criteria. Table 1 summarizes the baseline patient characteristics. Median age for the entire cohort was 65 (range, 34-83) years. Median follow-up for alive patients was 59.4 (range, 14.5-125.3) months. Approximately 183 patients (91.5%) received concurrent chemotherapy with radiation therapy. Ninety-four patients (47%) had stage IIIA disease, and 106 patients (53%) had stage IIIB disease. A total of 102 patients (51%) experienced a recurrence (defined as locoregional or distant failure).
We then stratified the patient population into CT (n ¼ 95) and PET/CT groups (n ¼ 105) on the basis of the nature of the imaging obtained for each patient after the end of RT (detailed in the Materials and Methods section). Patient characteristics stratified according to the CT-and PET/CT-based surveillance imaging Table 1 (Table 2) . Consequently, the significance of the PET/CT group who received more adjuvant chemotherapy and the CT group who received more neoadjuvant chemotherapy is unclear.
Patterns of Failure Between CT and PET/CT Groups
We next examined the patterns of failure between the 2 patient cohorts. There were 52 recurrences in the CT group and 50 in the PET/CT group (54.7% and 47.6% of their respective cohorts), which reflects the similarity of disease characteristics between the 2 populations (P ¼ .33; Table 3 ). There were 28 and 23 primary tumor failures in the CT and PET/CT groups, respectively (P ¼ .26). The PET/CT group did have more lymph node recurrences detected (10 vs. 3), but this did not meet statistical significance (P ¼ .09). A similar trend was observed with respect to extrathoracic lymph node recurrence, with 7 failures in the PET/CT group as opposed to 3 in the CT group (P ¼ .34). Conversely, in the CT group more bone metastases were detected as opposed to the PET/CT group, although this did not meet statistical significance (7 vs. 2; P ¼ .09). Overall, the specific patterns of failure were proportionally similar between the 2 groups, and no significant differences were observed with any of the patterns of failure (Table 3) . However, the small patient numbers might have disguised a potential benefit of PET/CT in discerning lymph node metastasis and CT in identifying bone metastasis.
Survival Comparison Between PET/CT and CT Surveillance Groups and Inclusion of Covariates
Median event-free survival (EFS) for the entire cohort was 26.7 months and median OS was 41.2 months. Outcomes were subsequently stratified according to surveillance imaging group (Figure 2 ). There was no statistical difference in OS between the 2 groups (median OS: CT group, 41.2 months; PET/CT group, 41.3 months; P ¼ .59; Figure 2A) . Similarly, there was no statistical difference in EFS (P ¼ .59), local-regional failure-free survival (LRFS; P ¼ .92), or distant metastases-free survival (DMFS; P ¼ .30) between the 2 surveillance groups (Figure 2B-D) . Consequently, these results suggest that surveillance after radiation treatment in stage III NSCLC patients with routine PET/CT 
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imaging affords no benefit with respect to local or distant relapse detection or associated survival benefit over CT imaging. We next generated a multivariate model to assess whether covariates of interest, including surveillance group stratification, were associated with clinical end points. Similar to the aforementioned log rank tests, stratification to the PET/CT imaging group was not associated with differences in clinical end points, including OS, EFS, LRFS, and DMFS (Table 4) . Karnofsky performance status >80, stage IIIB disease, and the use of concurrent chemotherapy also were not associated with changes in clinical outcome (Table 4) 
Discussion
In this study we examined whether a PET/CT-based strategy carries any benefit in detecting locoregional as well as distant recurrence over a CT-based strategy in stage III NSCLC patients who are treated with definitive radiation and do not experience disease recurrence within 6 months. Because of the improved sensitivity and specificity of PET/CT over CT, we hypothesized that we would observe earlier detection of local as well as distant recurrence, which could then lead to rapid deployment of salvage therapies, for which multiple randomized clinical trials have shown a survival benefit. 12, 13 In this context, our pertinent findings were as follows. First, we found that treatment characteristics were similar 
Figure 2 (A) Overall Survival (OS), (B) Event-free Survival (EFS), (C) Local Recurrence-free Survival (LR), and (D) Distant Metastasisfree Survival (DM) Stratified on the Basis of Imaging Group
Abbreviations: CT ¼ computed tomography; PET ¼ positron emission tomography.
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Clinical Lung Cancer March 2017 -145 between the 2 groups, as were the patterns of failure (Tables 2 and  3) . Second, the PET/CT-based group had OS, EFS, LRFS, and DMFS rates similar to the CT-based group in a cohort of stage III NSCLC patients treated with definitive RT (Figure 2 and Table 4 ). This suggests that a PET/CT-based surveillance strategy confers no additional benefit in clinical outcomes in this patient population despite its improved sensitivity and specificity. This nonrandomized comparative effectiveness study was subject to confounding that could have altered the results because of selection bias in assigning patients to a given surveillance strategy (eg, if higher-risk patients were routinely selected to undergo PET/ CT surveillance). However, we do not believe that this imbalance occurred in the current patient cohort for 2 reasons. First, we assessed for systematic differences in the patient, disease, and treatment characteristics of these 2 groups. If the surveillance regimen was strongly correlated with prognostic factors, this association would have been evident in this comparison. However, none of the many prognostic factors that we assessed corresponded with surveillance approach, and thus we concluded that, as we hypothesized, these choices were being made according to individual physician preference among the multiple (approximately 25) medical and radiation oncologists at our institution. Second, even in the scenario in which higher-risk patients were more frequently allocated to the PET/CT regimen (for factors for which we could not account in our comparison), we would anticipate higher recurrence and lower survival rates in this group. As noted, recurrence and survival patterns were very similar.
There is accumulating evidence that PET/CT has improved sensitivity and specificity over standard CT in detecting NSCLC recurrence, although there have been few reports comparing the 2 directly.
6,14,15 Antoniou et al reported that PET/CT imaging performed 6 months after treatment for lung cancer was a prognostic marker for OS and identified recurrence over 40% of the time even when there was no suspicion for recurrence. 7 However, the benefit of PET/CT imaging over standard CT imaging was not compared. In another report PET/CT and CT imaging were compared in lung cancer surveillance in stage I patients after lobectomy, and PET/CT imaging indeed was more sensitive and specific. 8 However, in this study PET/CT was compared with the noncontrast CT obtained during PET imaging; therefore, it is possible that the use of a contrast CT would have mitigated this benefit. In a prospective study of 100 NSCLC patients, PET/CT imaging obtained 3 months after treatment detected more instances of progressive disease than CT alone and enabled rapid initiation of salvage therapy. 10 However, this included small patient numbers, did not address the role of PET/CT in long-term surveillance of advanced stage NSCLC patients, and did not report long-term outcomes. Overall, there have been few studies to examine this issue and most have had small patient numbers and typically involve patients in the postoperative setting. Consequently, our study is unique in its relatively large size and examination in the setting after radiation treatment.
Because of the dearth of evidence, current NCCN guidelines do not recommend the use of PET/CT in the post-treatment surveillance period. 3 Our data appear to support this recommendation.
However, our findings that PET/CT does not confer any benefit in early detection of disease recurrence is surprising. Indeed, there have been multiple reports that tumor metabolism determined using PET/CT Versus CT Surveillance in Stage III NSCLC PET/CT has significant prognostic value in the post-radiation setting, [16] [17] [18] [19] [20] [21] although these studies do not address whether serial PET/CT imaging in the post-treatment setting confers additional prognostic benefit. Our hypothesis for our unexpected findings is that close surveillance with CT scans (every 3-4 months for the first 2 years) can detect abnormalities that can then be further evaluated with PET/CT. A contributing factor might be the extension of chest CT scans at our institution to the upper abdomen, which capture the adrenal glands and liver, 2 common sites of metastasis. 22 Therefore, patients are likely not presenting with substantially greater volume of disease to influence survival, and the advantage of PET/CT over CT in terms of sensitivity and specificity might be less robust in this study.
Other than the limitations inherent in any retrospective analysis, there are constraints on the interpretation of the results in this study. First, the results are partially dependent on the quality of the imaging modalities and interpretations of them at the institutional level. Second, neither of these strategies addresses the detection of brain metastases, which are common in lung cancer. However, routine brain imaging is not recommended in patients with stage III disease, and therefore was not directly related to the current study. Finally, the choice of PET/CT versus CT scan, although not because of any known factors, was also not likely completely random and was in some patients on the basis of clinical gestalt, which can be difficult to tease out. Other than the approaches we used to limit selection bias outlined previously, we also attempted to further decrease heterogeneity and potential confounding factors by limiting our analysis to stage III patients and the post-treatment surveillance window to the 18-month period after radiation treatment. The latter was done because PET/CT use dramatically decreased 18 months after treatment. Our design also excluded patients whose treatment failed <6 months after treatment, because these patients did not accumulate multiple post-treatment scans. This exclusion, in addition to the single institution nature of the study, likely explains the finding that the median OS of 41.2 months in the study cohort is superior to the reported median OS of 28 months in the 60-Gy arm of Radiation Therapy Oncology Group 0617, 23 despite similar treatments. Although these exclusion criteria allowed for a homogeneous study population to allow for assessment of long-term surveillance trends, they also limit the generalizability of our conclusions.
Conclusion
We report on the largest series, to our knowledge, to examine the differences between post-treatment imaging surveillance in stage III NSCLC patients after definitive radiation treatment. We found that there were no differences in patterns of failure or survival outcomes between the 2 strategies. Although we are currently performing an analysis to further elucidate the cost-effectiveness of surveillance regimens, our data provide the best evidence to date that supports the current NCCN guidelines that recommend CT-only surveillance in this context.
Clinical Practice Points
There are few data to support the use of PET/CT in routine surveillance of locally-advanced NSCLC patients who complete definitive radiation and in whom treatment does not fail within the initial 6 months. To address this knowledge gap, we report the largest series to our knowledge to evaluate the relative benefit of PET/CT surveillance over CT alone in stage III NSCLC after radiation treatment. Results of our study suggest that routine PET/CT surveillance confers no additional benefit over CT alone in detecting local or distant failure. These findings will be of interest to radiation, medical, and surgical oncologists in helping guide how best to follow locallyadvanced NSCLC patients after definitive therapy. Currently, national guidelines do not endorse the use of PET/CT in this setting, and the data presented in this study support this recommendation.
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